Natera a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, will feature its recently expanded Panorama non-invasive prenatal test (NIPT), which is now validated for screening twin pregnancies, at the Society for Maternal-Fetal Medicine (SMFM) Annual Meeting in Dallas, Jan. 29 to Feb. 3, 2018 (booth No. 161).
Panorama is the first NIPT that can screen twin pregnancies for zygosity (identical or non-identical twins) and determine gender for each twin as early as 9 weeks’ gestation. It is the only NIPT that differentiates between maternal and fetal DNA, which enables women to learn more about their pregnancies through a simple blood draw from the mother, posing no risk to the babies.
Vistara, an NIPT that screens single-gene disorders and was launched in mid-2017, also will be showcased at the meeting. The test complements Panorama and screens for conditions that have a combined incidence rate of 1 in 600, which is higher than that of Down syndrome.
“We look forward to sharing our new NIPT technology for screening twin pregnancies with maternal-fetal medicine specialists at the SMFM conference,” said Kimberly Martin, M.D., Natera’s Senior Medical Director for Women’s Health. “Early, highly accurate zygosity screening with Panorama can help clinicians identify monochorionic pregnancies, which are at higher risk for serious medical complications such as twin-twin transfusion syndrome, and which studies show are misclassified approximately 19 percent of the time with ultrasound alone.3”
A Lunch and Learn session titled “Aneuploidy to Zygosity: Clinical advantages of SNP-based screening for twins,” also will be presented by Dr. Martin on Friday, February 2. Pre-registration is required.
Please Visit for More Reports on NIPT : http://www.dpiresearch.com/